The COVID-19 pandemic is caused by the coronavirus SARS-CoV-2. Drugs for the treatment of this disease are urgently needed. The antiviral compound EIDD-2801 (molnupiravir, pictured above) has been identified as a potential drug candidate against COVID-19 and is currently in phase II clinical trials. The existing route for its synthesis, however, gives EIDD-2801 from uridine in a rather low yield of 17 %.
C. Oliver Kappe, Doris Dallinger, University of Graz, Austria, and colleagues have developed an improved synthesis of EIDD-2801 from uridine (pictured below) by strategically reordering the synthetic steps. The reaction sequence starts with the activation of uridine with 1,2,4-triazole and continues with a telescoped acetonide protection/esterification and a telescoped hydroxyamination/acetonide deprotection. Telescoped reaction sequences consist of two or more than one one-pot procedures that are performed back-to-back without a work-up step in-between. A continuous flow process was used for the final acetonide deprotection, which improved selectivity and reproducibility.
Compared to the original route, the yield of EIDD-2801 was improved to 61 %. This strategy also requires fewer isolation steps because of the two telescoped procedures (acetonide protection/esterification and hydroxyamination/acetonide deprotection) included within the five‐step route.
- A High‐Yielding Synthesis of EIDD‐2801 from Uridine,
Alexander Steiner, Desiree Znidar, Sándor B. Ötvös, David R. Snead, Doris Dallinger, C. Oliver Kappe,
Eur. J. Org. Chem. 2020.
Also of Interest
- 05 October 2021
Molnupiravir significantly reduces risk of hospitalization and/or death, according to Merck
- 04 August 2021
Efficient synthesis from cheap and easily available cytidine
Research Highlight: How Molnupiravir Causes SARS-CoV-2 to Mutate and Die
Mechanism might apply to various viral polymerases and could explain broad-spectrum antiviral activity of molnupiravir
- 19 November 2020
Improved preparation of EIDD‐2801, currently in clinical trials for COVID-19 treatment
- 09 December 2020
Repurposed ribonucleoside analogue inhibitor of influenza viruses